Insomnia in Alzheimer Disease: Moving Toward Safer, More Effective Sleep Solutions

Sleep Disorders
Insomnia in Alzheimer Disease
1.0 AMA PRA Category 1 Credit(s) 1.0 ANCC Contact Hours
Launch Date:
December 20, 2019
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Primary care physicians, nurse practitioners, and physician assistants in geriatric practice

Relevant Terms:

Alzheimer Disease, Insomnia, Dementia

Alon Y. Avidan, MD, MPH, HAAN, FAASM

Professor and Vice Chair
Department of Neurology
David Geffen School of Medicine
Sleep Disorders Center
University of California, Los Angeles
Los Angeles, California

Alon Y. Avidan, MD, MPH is Professor and Vice Chair in the Department of Neurology at the David Geffen School of Medicine at UCLA, and Director of the UCLA Sleep Disorders Center.

He completed his Neurology Residency at the Georgetown University Medical Center. After residency, he completed fellowship training in Sleep Medicine at the Cleveland Clinic. He was Principal Investigator of a National Heart, Lung & Blood Institute, NIH, Sleep Academic Award. He has published over 100 chapters, letters to the editor, peer reviewed articles and edited five textbooks in sleep medicine. His research focus includes the impact and prognostic implications of sleep disturbance on underlying neurologic disorders. He enjoys educating physicians and the public about sleep disorders and has recently received the American Academy of Sleep Medicine (AASM) 2014 Excellence in Education Award.

Larry Culpepper, MD, MPH

Professor of Family Medicine
Department of Family Medicine
Boston University School of Medicine
Boston, Massachusetts

Dr. Culpepper, Professor of Family Medicine, was the founding Chairman of the Department. He received his M.D from Baylor College of Medicine and his M.P.H. from Boston University. He has served as President of the North American Primary Care Group (NAPCRG), Chairman of the Research Committee of the Society of Teachers of Family Medicine (STFM), and is the Chairman of the Board of Rhode Island Public Health Foundation. He is a Primary Care Fellow of the Federal Health Resources and Services Administration, and has chaired or served as a member of research grant review committees for 5 NIH and other federal agencies. He has received the STFM Excellence in Education, the STFM-NAPCRG Hames Research awards, and the Maurice Wood Award for Lifetime Contribution to Primary Care Research (2010) and was elected to the Institute of Medicine in 1998. The BU School of Public Health recognized him with its 2008 BUSPH Distinguished Alumni Award. He has conducted research in otitis media, and school-based and community interventions to improve pregnancy outcomes and to prevent teen pregnancies and has been the principal investigator of an AHRQ funded center for patient safety research devoted to low income and minority vulnerable populations in ambulatory care settings, principal investigator of interventions to improve the care of uninsured patients and urban patients with diabetes and depression, co-principal investigator of a study to decrease delays in CHC patient follow-up for abnormal mammography, and co-investigator of a long term study of the course of anxiety disorders in primary care settings. Dr Culpepper co-chaired a panel on Otitis Media with Effusion for the American Academy of Family Physicians, the American Academy of Pediatrics, and the American Academy of Otolaryngology-Head and Neck Surgery, and is a member of the AAP-AAFP panel on acute otitis media. He founded and chaired the board of the Rhode Island Public Health Foundation (1992-2011). He is a member of The Depression and Bipolar Support Alliance and the Anxiety Disorders Association of America Scientific Advisory Boards. He currently is the primary care member of an Institute of Medicine Committee on the Assessment of Ongoing Efforts in the Treatment of PTSD (2011-15). He was the initial family medicine editor of UpToDate and is the editor of the Journal of Clinical Psychiatry Primary Care Companion.

1. Discuss the consequences of untreated insomnia in AD
2. Describe the bidirectional relationship between sleep disturbances and neurocognitive disorders
3. Integrate insomnia assessment into routine encounters with patients with AD
4. Review clinical trial data for emerging therapies for insomnia in AD
5. Develop comprehensive and safe management strategies for patients with insomnia and AD

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and MedEdicus LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. 

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


Alon Y. Avidan, MD, MPH, HAAN, FAASM
Consulting fees from Eisai Inc; Harmony Biosciences, LLC; and Merck & Co., Inc
Data and Safety Monitoring funding from Balance Therapeutics; and Merck & Co., Inc

Larry Culpepper, MD, MPH
Consulting fees from Acadia Pharmaceuticals, Inc; Allergan; Eisai Inc; Merck & Co., Inc; Supernus Pharmaceuticals, Inc; and Takeda Pharmaceuticals USA, Inc
Ownership interest less than 5% (stocks, stock options, or other ownership interest excluding diversified mutual funds) in M-3 Information, LLC

Planners and Managers 
The PIM planners and managers have nothing to disclose. The MedEdicus planners and managers have nothing to disclose.

Method of Participation and Request for Credit
There are no fees for participating in and receiving CME/CE credit for this activity. During the period December 20, 2019, through December 20, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation. Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, a certificate will be made available immediately.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by Postgraduate Institute for Medicine ( and MedEdicus LLC.

This activity is supported by an independent educational grant from Merck & Co., Inc. 

© 2019 MedEdicus LLC



Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above